Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221605 | 0.91 | ALOX5 (0.37) | EPHX2FFAR1CCNT1PTPN11CNR2 | |
| SCHEMBL4216973 | 0.87 | EPHX2 (0.40) | EPHX2FFAR1LTA4HVSIRPTPN11 | |
| SCHEMBL4605966 | 0.86 | HTR7 (0.40) | EPHX2PPIDFFAR1PPARAPTPN11 | |
| SCHEMBL4361050 | 0.85 | KDM4E (0.38) | FFAR1CCNT1VSIRPTPN11CNR2 | |
| SCHEMBL4361055 | 0.85 | KDM4E (0.38) | FFAR1CCNT1VSIRPTPN11CNR2 | |
| Trifluoroacetic Acid SCHEMBL4362273 | 0.83 | EPHX2 (0.41) | EPHX2PPIDFFAR1PPARAPTPN11 | |
| SCHEMBL4219912 | 0.78 | ALOX5 (0.39) | EPHX2FFAR1PTPN11CNR2ALOX5 | |
| SCHEMBL6531485 | 0.78 | PPID (0.36) | EPHX2PPIDVSIR | |
| SCHEMBL4217552 | 0.76 | HTR7 (0.42) | FFAR1PTPN11CNR2ALOX5PPARG | |
| SCHEMBL6531486 | 0.75 | PPID (0.37) | EPHX2PPIDFFAR1CCNT1VSIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | EPHX2 2703/4885PPID 2789/4885FFAR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.